Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients

doi:10.1097/CAD.0000000000001107

中山醫學大學機構典藏 CSMUIR > 中山醫學大學研究成果 > 期刊論文 > Item 310902500/23709

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/23709

Title:	Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non-small cell lung cancer patients
Authors:	Lee, PH;Chen, KC;Hsu, KH;Huang, YH;Tseng, JS;Yang, TY;Chang, GC
Keywords:	anaplastic lymphoma kinase (ALK);dyslipidemia;lorlatinib;lung adenocarcinoma
Date:	2021
Issue Date:	2022-08-05T09:41:38Z (UTC)
Publisher:	LIPPINCOTT WILLIAMS & WILKINS
ISSN:	0959-4973
Abstract:	Anaplastic lymphoma kinase (ALK) translocation is a rare driver mutation in lung cancer. This study was aimed to report on the efficacy of lorlatinib in real-world practice and to evaluate the impact of prior ALK inhibitor treatments. We retrospectively evaluated patients with ALK-positive non-small cell lung cancer (NSCLC) treated with lorlatinib regarding its efficacy, the impact of prior ALK inhibitor treatments and the adverse events, in particular dyslipidemia. A total of 22 ALK-positive patients were analyzed. All patients had received at least one second-generation ALK inhibitor(s), while 12 patients had a history of crizotinib treatment. For lorlatinib, the objective response rate was 35.7%, and disease control rate was 64.3%. Their progression-free survival (PFS) was 6.2 months. With prior therapies, patients receiving only second-generation ALK inhibitor(s) treatment showed PFS longer than those with both crizotinib and second-generation ALK inhibitor(s) treatments (15.2 vs. 6.2 months). Moreover, patients who showed benefits from prior ALK inhibitor(s) also had a PFS longer than those who did not (6.5 vs. 3.5 months). Regarding adverse events, 94.7% of patients had dyslipidemia and 21.1% of them were in grade 3 or 4. None of these patients discontinued the treatment due to dyslipidemia. No acute complication occurred with dyslipidemia. The real-world efficacy of lorlatinib and adverse events were similar to those reported in clinical trials. Interestingly, the history and responses of prior ALK inhibitor treatments may influence the efficacy of subsequent lorlatinib treatment.
URI:	http://dx.doi.org/10.1097/CAD.0000000000001107 https://www.webofscience.com/wos/woscc/full-record/WOS:000708619800014 https://ir.csmu.edu.tw:8080/handle/310902500/23709
Relation:	ANTI-CANCER DRUGS ,2021,v32,issue 10, P1099-1104
Appears in Collections:	[中山醫學大學研究成果] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	156	View/Open

Loading...